ATNM.A (ATNM.A) News
Follow ATNM.A (ATNM.A) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 3 public stories across 2 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Actinium's ATNM — 400 Shows Antitumor Activity in Preclinical Lung Cancer Models
Actinium Pharmaceuticals reported preclinical antitumor activity for ATNM-400, its actinium-225 radiotherapy, across lung, colorectal and ovarian cancer models. In non-small cell lung cancer, ATNM-400 showed standalone a
NEWS | Oct 16, 2026, 12:33 PM UTC
L
Actinium Pharmaceuticals to Present Early Phase 1 Data for ATNM — 400 in Prostate Cancer at EANM
Actinium Pharmaceuticals will present early Phase 1 results for prostate cancer therapy ATNM-400 on October 19, 2026, at EANM in Vienna. Initial clinical data support advancing the non-PSMA-targeted radiotherapy for meta
NEWS | Oct 15, 2026, 12:38 PM UTC
L
Actinium Pharmaceuticals Names Matt David Chief Financial Officer
Actinium Pharmaceuticals appointed Matt David chief financial officer to lead financial operations, capital markets and investor relations. David most recently served as CorMedix's executive vice president and chief busi
NEWS | Oct 15, 2026, 11:34 AM UTC